Compare Micron Technology, Inc. (MU) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Micron Technology, Inc. vs Spyre Therapeutics Inc. Common Stock — how do they compare? Micron Technology, Inc. trades at $877.92 (market cap $1.08T), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B). The key difference: Micron Technology, Inc. is far larger — about 143.6× Spyre Therapeutics Inc. Common Stock's market cap, and Micron Technology, Inc. pays a 0.06% dividend while Spyre Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Micron Technology, Inc. for 49 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| MU | SYRE | |
|---|---|---|
Market Cap | $1.08T | $7.52B |
Volume | 28,906,235 | 1,441,031 |
Sector | Technology | Health |
52-Week High | $1.21K | $108.92 |
52-Week Low | $191.94 | $22.18 |
Typical Hold Time | 49 Days | 0 Days |
Enterprise Value | $1.04T | $6.52B |
Dividend Yield | 0.06% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Micron Technology (MU) is trading at $914.13, down 7.57% today, following strong recent performance. The stock shows robust fundamentals with a P/E of 12.82, net income margin of 63.8%, and consistent earnings beats. Technical indicators show a bullish moving average signal despite today's pullback, with support at $978. The company benefits from strong AI-driven memory demand and strategic customer agreements covering 35% of revenue through 2030.
Outlook remains positive with analyst consensus at 82.85% buy ratings and $1,590 price target. Key opportunities include sustained AI memory demand and reduced cyclicality through long-term contracts. Risks include potential growth deceleration in 2028 and market volatility. The stock's current valuation appears reasonable given strong profitability and growth trajectory.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Micron Technology, Inc.
Micron historically focused on designing and manufacturing DRAM for PCs. The firm then expanded into the NAND flash memory market. It increased its DRAM scale with the purchase of Elpida (completed in mid-2013) and Inotera (completed in December 2016). The firm's DRAM and NAND products tailored to PCs, data centers, smartphones, game consoles, automotives, and other computing devices.
Read more on MU →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
